Newsroom

Strive to Deliver Breakthroughs

  1. February 14, 2025

    Harbour BioMed Announces Business Progress and Update

    Cambridge, MA, Rotterdam, NL, Shanghai, CN – February 13, 2025   Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceu...

    View more
  2. February 05, 2025

    Harbour BioMed Receives NMPA IND Clearance for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease

    Cambridge, MA, Rotterdam, NL, Shanghai, CN — February 4, 2025   Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceuti...

    View more
  3. January 10, 2025

    Harbour BioMed Announces License Agreement with Windward Bio for HBM9378/SKB378, an Anti-TSLP Fully Human Antibody for Immunological Diseases

    Cambridge, MA, Rotterdam, NL, Shanghai, CN — January 10, 2025   Harbour BioMed (HKEX: 02142, the “Company”), a global biophar...

    View more
  4. November 15, 2024

    Harbour BioMed Appoints Dr. Raymond Zheng as Chief Business Officer

    Cambridge, MA, Rotterdam, NL, Suzhou, CN — November 14, 2024   Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceuti...

    View more
  5. November 08, 2024

    Harbour BioMed Announces Submission of IND Application for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease

    Cambridge, MA, Rotterdam, NL, Suzhou, CN – November 8, 2024   Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutic...

    View more
  6. October 10, 2024

    Harbour BioMed Announces Publication of the Phase I Study Results for Porustobart in Combination with Toripalimab in Advanced Melanoma and Other Solid Tumors

    Cambridge, MA, Rotterdam, NL, Suzhou, CN — October 9, 2024   Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical...

    View more
  7. September 14, 2024

    Harbour BioMed Announces the Latest Clinical Data on the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024

    Cambridge, MA, Rotterdam, NL, Suzhou, CN — September 14, 2024   Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceuti...

    View more
  8. August 28, 2024

    Harbour BioMed Announces 2024 Interim Results

    Harbour BioMed (“HBM”, or the "Company”; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and c...

    View more
  9. July 26, 2024

    Harbour BioMed to Present the Latest Progress of the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024

    Cambridge, MA, Rotterdam, NL, Suzhou, CN — July 25, 2024   Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical ...

    View more
  10. July 19, 2024

    Harbour BioMed Announces Positive Profit Alert for 2024 Interim Results

    Cambridge, MA, Rotterdam, NL, Suzhou, CN – July 19, 2024   Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical ...

    View more